We develop medicines to ease the burden of neglected diseases on underserved communities worldwide.
MENU
CLOSE
.svg){kind=logo}
.svg){kind=logo}
.svg){kind=icon}
MENU
CLOSE
We develop medicines to ease the burden of neglected diseases on underserved communities worldwide.
READ MORE
2026 Annual Report
A joint call from Product Development Partnerships for Sustained Funding to EDCTP under the Next Framework Programme for Research and Innovation (FP10)
KEY STAT
001
Over 1 billion people suffer from neglected tropical diseases
KEY STAT
002
149 countries are in a NTD pandemic
KEY STAT
003
There are 21 distinct NTDs and disease groups recognised
WHO WE ARE
MDGH has removed the reliance on a commercial return on investment in the development of medicines to focus on providing solutions to some of the world's most urgent health challenges. As a not-for-profit pharmaceutical company, MDGH is on a mission to eliminate neglected diseases by undertaking the development, regulatory approval and manufacture and supply of medicines for many of the world’s most underserved communities. We are currently developing two medicines: moxidectin and dovramilast. Together, these medicines are targeting seven different neglected diseases that collectively impact more than 1 billion people.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Between 2005 and 2024, more spacecraft were sent to the moon than new U.S. FDA-approved medicines were developed for neglected diseases and tuberculosis. We’re addressing this innovation gap by developing improved treatments that can transform health outcomes for people in low- and middle-income communities.
We’re already making progress in addressing global health inequities, but we’re just one piece of a larger puzzle. Our work and its impact on global health is only made possible through productive partnerships with industry, research institutes, governments, impact investors and donors.
Medicines Development for Global Health (MDGH) develops new medicines for people and communities who are disadvantaged by the traditional consideration of market returns.
In 2018, we became the first solo not-for-profit company to achieve FDA approval for a novel medicine, when we registered moxidectin, the first new treatment for river blindness (onchocerciasis) in 20 years. Supported by our collaborators, we are working towards making a lasting change in the lives of people affected by neglected diseases.
Of the approximately 400 New Drug Applications (NDAs) approved in the years 2009 to 2020, only 10 were for neglected infectious diseases, which affect more than a billion people globally. As a social enterprise, we take an innovative approach to developing new and improved treatments for neglected diseases, helping to elevate the health status of affected communities in low- and middle-income countries.
We are addressing important and unmet medical needs in global health through the development and delivery of new medicines. Our development model is resource-efficient and cost-effective, and built on identifying and integrating the necessary expertise from each part of the development pathway at the time that expertise is needed.
We work constructively to address global health inequities, but our work is just one piece of a larger puzzle. Our team relies on strong collaboration networks and continuously seeks fruitful and effective partnerships to increase our chances of reducing the burden of neglected diseases.
MDGH consists of independent legal entities in the following countries which collaborate in pursuit of our mission:
Medicines Development for Global Health Limited is a not-for-profit pharmaceutical company incorporated in Australia (Australian Company Number 116 977 523) and registered as a charity with the Australian Charities and Not-for-Profits Commission (Australian Charity Number 116 977523).
Medicines Development for Global Health Limited was incorporated on 3 June 2015 as a company limited by guarantee in the UK. The company is a registered charity in England and Wales (charity number 1200620).
Medicines Development for Global Health Inc. (a tax-exempt 501(c)(3) public charity) was incorporated on 6 July 2021 as a non-profit corporation.
Medicines Development for Global Health acknowledges the sovereignty of the Peoples of the Boon Warrung/Woj Wurrung clan(s) of the Kulin nation of the land on which MDGH’s headquarters stand, and we pay our respects to their ancestors and Elders. We are here to achieve greater equity of access to good health globally, through the development of medicines for the treatment of neglected diseases, whilst respecting the right to self-determination of First Peoples everywhere.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523
